Research programme: metabolic disease therapeutics - Second Genome
Latest Information Update: 28 Aug 2022
At a glance
- Originator Second Genome
- Developer Mayo Clinic; Pfizer; Second Genome
- Class Bacteria; Obesity therapies; Peptides; Small molecules
- Mechanism of Action Microbiome modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Metabolic disorders; Obesity
Most Recent Events
- 28 Aug 2022 No recent reports of development identified for research development in Obesity in USA
- 28 Sep 2020 No recent reports of development identified for research development in Metabolic-disorders in USA
- 12 Sep 2018 Early research in Obesity and Metabolic disorders is ongoing in USA (Second Genome website, September 2018)